Form 10-K Passage BIO, Inc. For: Dec 31

Related Keywords

Pennsylvania ,United States ,Taiwan ,Japan ,United Kingdom ,Argentina ,Philadelphia ,Washington ,Brazil ,China ,Delaware ,Commerce Square ,California ,Canada ,Russia ,Ukraine ,Germany ,New Jersey ,Israel ,Princeton ,Newfoundland ,University Of Pennsylvania ,Ireland ,Switzerland ,America ,German ,Irish ,American ,Simona King ,Maxine Gowen ,Sandip Kapadia ,Athena Countouriotis ,Edgarb Cale ,Michael Kamarck ,Tom Woiwode ,James Wilson ,Saqib Islam ,William Chou ,Derrell Porter ,Us Congress ,Glaxosmithkline ,Revenue Service ,Office Of Tissues ,Trademark Office ,Public Company Accounting Oversight Board United States ,Office For Civil Rights ,Centers For Medicare Medicaid Services ,National Institutes Of Health ,Research Programs ,Passage Bio Inc ,Us Supreme Court ,Nasdaq Stock Market ,Health Care ,Alector Inc ,Penn Orphan Disease Center ,Us Export Administration Regulations ,Laboratory Lease Agreement ,Takeda Pharmaceutical Company ,Forum Provision ,Other Research Programs ,Medicaid Services ,Medicaid Drug Rebate Program ,Rare Pediatric Disease Priority Review Voucher Program ,Us Department Of Health ,Development Strategy ,Disease Center ,Commission File Number ,Institute For Human Gene Therapy Of Penn ,Public Health Service ,Delaware Supreme Court ,Company Lease Agreement ,Our Mission ,Mitigation Of Clinical Development Risk ,Office Of Inspector ,Unnamed Research Program ,Health Insurance Portability ,Nasdaq ,Development Expenses ,Centers For Medicare ,Product Development ,Therapeutics Inc ,Catalent Biologics Inc ,Clinical Health ,Genetic Technologies Corporation ,Denali Therapeutics Inc ,European Commission ,Children Health Insurance Program ,Drug Administration ,Data Monitoring Committee ,Exchange Commission ,Securities Exchange ,Program Specific Expenses ,Us Department Of Justice ,Institutional Biosafety Committee ,Trustees Of The University Pennsylvania ,Advisory Committee ,Eli Lilly Co ,Exploratory Research Program ,Aviadobio Ltd ,European Union ,Corporation Law ,Public Company Accounting Oversight Board ,Gene Therapies Advisory Committee ,Health Information Technology For Economic ,Good Laboratory Practices ,Pediatric Research Equity ,Company Ibrs ,Human Services ,Gene Therapy Program ,Supreme Court ,American Medical Association ,Mark One ,Exact Name ,Its Charter ,Zip Code ,Nasdaq Global Select Market ,Securities Exchange Act ,Interactive Data File ,Regulations T ,Sarbanes Oxley Act ,Nasdaq Global Market ,Definitive Proxy Statement ,Annual Report ,Financial Condition ,Securities Act ,Passage Bio ,Orphan Disease Center ,Temporal Lobe Epilepsy ,Investigational New Drug ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Fast Track Designation ,Advanced Therapy Medicinal Product ,Metachromatic Leukodystrophy ,Detect Lysosomal Storage Disorders ,Catalent Maryland ,Catalent Biologics ,Selecting Product ,Early Development Risk ,Programs Prior ,Chief Scientific Advisor ,Clinical Development Risk ,Natural History Study ,History Study ,Clinical Results ,Biologics License Application ,Vector Serotypes ,Clinical Dementia Rating ,Clinical Trial ,Amyotrophic Lateral Sclerosis ,Collaboration Agreement ,Supply Agreement ,Princeton West Innovation ,National Institutes ,Prevail Therapeutics ,Eli Lilly ,Applied Genetic Technologies Corporation ,Syncona Limited ,Orchard Therapeutics ,Fbio Ltd ,Takeda Pharmaceutical Company Limited ,Penn Agreement ,Argentina Brazil ,Risks Related ,Federal Food ,Cosmetic Act ,New Drug Applications ,Public Health Service Act ,Good Laboratory ,Good Clinical Practice ,Standard Review ,Priority Review ,Gene Therapy ,Orphan Drug Act ,Drug Designation ,Rare Pediatric Disease Priority Review Voucher ,Consolidated Appropriations Act ,Track Designation ,Pediatric Research Equity Act ,Biologics Price Competition ,Innovation Act ,Inspector General ,Civil Rights ,Social Security Act ,Accountability Act ,Anti Kickback Statute ,Patient Protection ,Affordable Care Act ,Education Reconciliation Act ,False Claims Act ,Fraud Enforcement ,Recovery Act ,Health Information Technology ,Clinical Health Act ,Physician Payments Sunshine Act ,Health Insurance Program ,Inflation Reduction Act ,Human Capital ,Princeton West Innovation Campus ,Two Commerce Square ,Financial Position ,Good Clinical Practices ,Independent Data Monitoring Committee ,Risk Evaluation ,Mitigation Strategies ,Medication Guide ,Human Gene Therapy ,Advanced Therapies ,Biologics Evaluation ,License Agreement ,Competent Authorities ,Member States ,European Economic Area ,Paragon Bioscience ,Aviado Therapeutics ,Intellectual Property ,Orphan Drug ,Leahy Smith America Invents Act ,America Invents Act ,Molecular Pathology ,Drug Price Competition ,Patent Term Restoration Act ,Hatch Waxman Amendments ,Bayh Dole Act ,Orphan Drug Designations ,Pediatric Disease ,Physician Payment Sunshine Act ,Employee Matters ,Managing Growth ,Chief Scientific ,California Consumer Privacy Act ,Tax Cuts ,Jobs Act ,Internal Revenue Code ,Internal Revenue Service ,Coronavirus Aid ,Economic Security Act ,Continued Assistance ,Unemployed Workers Act ,Administration Regulations ,Foreign Assets Controls ,Corrupt Practices Act ,Jumpstart Our Business Startups Act ,Delaware General Corporation Law ,Federal Forum ,Federal Forum Provision ,California Attorney General ,California Privacy Rights Act ,General Data Protection Regulation ,Data Protection Act ,Protection Act ,European Union United States ,Privacy Shield ,Executive Order ,Standard Contractual Clauses ,Implementing Decision ,Unresolved Staff ,Mine Safety ,Common Equity ,Related Stockholder Matters ,Issuer Purchases ,Equity Securities ,Clean Room ,Clean Room Suite ,Acquired In Process Research ,Years Ended December ,In Process Research ,Sales Agreement ,Cash Used ,Accounting Policies ,Qualitative Disclosures ,Market Risk ,Accounting Standards Update ,Ended December ,Going Concern ,Financial Statements ,Significant Accounting ,Accounting Standards Codification ,Accounting Standards Updates ,Financial Accounting Standards Board ,Income Taxes ,Financial Instruments Credit Losses ,Financial Instruments ,Codification Improvements ,Fair Value Measurement ,Disposal Activities ,Lease Agreement ,Restated Research ,License Arrangement ,Incentive Plan ,Inducement Plan ,Stock Purchase Plan ,Stock Compensation ,Black Scholes ,Disclosure Controls ,Exchange Act ,Internal Control Over Financial ,Sponsoring Organizations ,Treadway Commission ,Internal Control ,Integrated Framework ,Regarding Foreign Jurisdictions ,Executive Officers ,Proxy Statement ,Security Ownership ,Certain Beneficial Owners ,Related Stockholder ,Certain Relationships ,Related Transactions ,Principal Accountant Fees ,Extension Presentation Linkbase ,Page Interactive Data File ,Registration Statement ,Executive Officer ,Chief Executive ,Principal Executive Officer ,Financial Officer ,Principal Financial ,Accounting Officer ,